Regeneron says ubamatamab shows 73% response rate and 11-month median PFS in LGSOC patients
REGN•Regeneron said ubamatamab showed a 73% objective response rate and 11-month median progression-free survival in patients with low-grade serous ovarian cancer. The company plans to advance the treatment into a confirmatory Phase 3 trial.
1. Study results
Regeneron said ubamatamab showed a 73% objective response rate and 11-month median progression-free survival in patients with advanced low-grade serous ovarian cancer. At the 800 mg dose, median duration of response was nine months.
2. Safety and next steps
Treatment-emergent adverse events occurred in all patients, with cytokine release syndrome in 90%; all cases of cytokine release syndrome were Grade 1 or 2. Grade 3 or higher serious treatment-emergent adverse events occurred in 21% of patients. Regeneron said it plans to advance ubamatamab into a confirmatory Phase 3 trial.
